TSLP and asthma: In the phase 3 trial, Tezepelumab, a monoclonal antibody targeting TSLP, significantly minimized exacerbation of symptoms across all seasons in patients with uncontrolled asthma, including those with seasonal and perennial allergies (Table 3) [213].